Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Non-Current Liabilities (2021 - 2023)

Arcturus Therapeutics Holdings (ARCT) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $497000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Other Non-Current Liabilities fell 82.28% year-over-year to $497000.0, compared with a TTM value of $497000.0 through Dec 2023, down 82.28%, and an annual FY2023 reading of $497000.0, down 82.28% over the prior year.
  • Other Non-Current Liabilities was $497000.0 for Q4 2023 at Arcturus Therapeutics Holdings, down from $976000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.7 million in Q3 2022 and bottomed at $358000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 3 years is $1.5 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities soared 163.7% in 2022, then plummeted 82.28% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $1.4 million in 2021, then skyrocketed by 101.15% to $2.8 million in 2022, then tumbled by 82.28% to $497000.0 in 2023.
  • Business Quant data shows Other Non-Current Liabilities for ARCT at $497000.0 in Q4 2023, $976000.0 in Q3 2023, and $1.3 million in Q2 2023.